Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
C$10.60
-3.8%
C$10.60
C$3.50
C$15.75
C$168.68MN/A12,671 shs3,402 shs
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
$0.41
-4.7%
$0.00
$1.69
$14.81
$993KN/A102,599 shs341,644 shs
Samsara Inc. stock logo
IOT
Samsara
$34.39
-0.8%
$34.68
$16.63
$40.54
$18.93B1.563.68 million shs3.22 million shs
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
C$0.45
+1.1%
C$0.43
C$0.35
C$0.66
C$50.64M0.8265,989 shs67,500 shs
Revive Therapeutics Ltd stock logo
RVV
Revive Therapeutics
C$0.08
+14.3%
C$0.08
C$0.07
C$0.25
C$5.79MN/A93,085 shs212,852 shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
0.00%0.00%0.00%0.00%0.00%
Samsara Inc. stock logo
IOT
Samsara
-0.78%+10.86%-12.74%+11.47%+79.68%
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
+1.12%+21.62%+18.42%+12.50%-26.23%
Revive Therapeutics Ltd stock logo
RVV
Revive Therapeutics
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Samsara Inc. stock logo
IOT
Samsara
1.084 of 5 stars
1.33.00.00.02.64.20.6
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
N/AN/AN/AN/AN/AN/AN/AN/A
Revive Therapeutics Ltd stock logo
RVV
Revive Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/AN/AN/AN/A
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/AN/AN/A
Samsara Inc. stock logo
IOT
Samsara
2.56
Moderate Buy$32.60-5.21% Downside
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
N/AN/AN/AN/A
Revive Therapeutics Ltd stock logo
RVV
Revive Therapeutics
N/AN/AN/AN/A

Current Analyst Ratings

Latest HEB, NSCI, BCT, IOT, and RVV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Samsara Inc. stock logo
IOT
Samsara
Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$42.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/AN/AC$3.34 per share3.17C$3.60 per shareN/A
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/AN/AN/AN/AN/A
Samsara Inc. stock logo
IOT
Samsara
$937.39M20.20N/AN/A$1.68 per share20.47
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
C$25.87M1.96C$0.05 per share8.93C$0.25 per share1.80
Revive Therapeutics Ltd stock logo
RVV
Revive Therapeutics
N/AN/AC$0.03 per share3.18C$0.02 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/A-C$0.38N/AN/AN/AN/AN/AN/A
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/A0.00N/AN/AN/AN/AN/A
Samsara Inc. stock logo
IOT
Samsara
-$286.73M-$0.53N/AN/AN/A-30.59%-22.90%-12.81%6/6/2024 (Estimated)
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
-C$16.96M-C$0.17N/AN/A-65.57%-47.87%-15.68%N/A
Revive Therapeutics Ltd stock logo
RVV
Revive Therapeutics
N/A-C$0.02N/AN/AN/AN/AN/A6/4/2024 (Estimated)

Latest HEB, NSCI, BCT, IOT, and RVV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/7/2024Q4 2024
Samsara Inc. stock logo
IOT
Samsara
-$0.08-$0.08N/A$0.05$258.56 million$276.27 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
N/AN/AN/AN/AN/A
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/AN/AN/AN/A
Samsara Inc. stock logo
IOT
Samsara
N/AN/AN/AN/AN/A
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
N/AN/AN/AN/AN/A
Revive Therapeutics Ltd stock logo
RVV
Revive Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
0.05
129.63
128.68
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/AN/A
Samsara Inc. stock logo
IOT
Samsara
N/A
1.50
1.46
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
71.36
1.52
1.11
Revive Therapeutics Ltd stock logo
RVV
Revive Therapeutics
N/A
6.14
6.03

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BriaCell Therapeutics Corp. stock logo
BCT
BriaCell Therapeutics
515.91 millionN/ANot Optionable
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
312.44 millionN/ANot Optionable
Samsara Inc. stock logo
IOT
Samsara
2,895550.52 million186.41 millionNot Optionable
Nanalysis Scientific Corp. stock logo
NSCI
Nanalysis Scientific
249112.54 millionN/ANot Optionable
Revive Therapeutics Ltd stock logo
RVV
Revive Therapeutics
N/A72.41 millionN/ANot Optionable

HEB, NSCI, BCT, IOT, and RVV Headlines

SourceHeadline
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVIDRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
tmcnet.com - April 23 at 8:07 AM
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic ProductRevive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
markets.businessinsider.com - April 18 at 8:03 AM
Revive Therapeutics Ltd.: Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVIDRevive Therapeutics Ltd.: Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
finanznachrichten.de - March 27 at 4:23 PM
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVIDRevive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
finance.yahoo.com - March 27 at 10:10 AM
Revive Therapeutics Ltd.: Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVIDRevive Therapeutics Ltd.: Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
finanznachrichten.de - March 19 at 11:42 AM
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVIDRevive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
markets.businessinsider.com - March 19 at 11:42 AM
Revive Therapeutics Ltd.: Revive Therapeutics Provides Corporate UpdateRevive Therapeutics Ltd.: Revive Therapeutics Provides Corporate Update
finanznachrichten.de - March 12 at 8:23 AM
Revive Therapeutics Provides Corporate UpdateRevive Therapeutics Provides Corporate Update
financialpost.com - March 12 at 7:08 AM
Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110
markets.businessinsider.com - February 26 at 8:53 PM
Revive Therapeutics Explores the Use of Bucillamine for Long COVIDRevive Therapeutics Explores the Use of Bucillamine for Long COVID
markets.businessinsider.com - February 1 at 9:20 AM
Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500
markets.businessinsider.com - January 31 at 7:29 PM
Revive Therapeutics Ltd. Announces Offering of Up to $3 MillionRevive Therapeutics Ltd. Announces Offering of Up to $3 Million
financialpost.com - January 24 at 7:03 PM
Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development CanadaRevive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada
tmcnet.com - January 16 at 8:29 AM
Revive Therapeutics Ltd.: Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of BucillamineRevive Therapeutics Ltd.: Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
finanznachrichten.de - January 10 at 2:05 PM
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of BucillamineRevive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
markets.businessinsider.com - January 10 at 9:05 AM
Travere Therapeutics expects Q4 net product sales from continuing operations to be about $40MTravere Therapeutics expects Q4 net product sales from continuing operations to be about $40M
msn.com - January 8 at 4:03 PM
Revive Therapeutics Announces Results of Annual General and Special Meeting of ShareholdersRevive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
markets.businessinsider.com - December 20 at 5:50 PM
Revive Therapeutics To Work With Attwill For Development Of Lyophilized Formulation Of BucillamineRevive Therapeutics To Work With Attwill For Development Of Lyophilized Formulation Of Bucillamine
markets.businessinsider.com - December 18 at 8:03 AM
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of BucillamineRevive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine
financialpost.com - December 18 at 7:07 AM
Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent ExposureRevive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
markets.businessinsider.com - October 17 at 4:48 PM
Revive Therapeutics Agrees With DRDC To Evaluate Bucillamine For Nerve Agent ExposureRevive Therapeutics Agrees With DRDC To Evaluate Bucillamine For Nerve Agent Exposure
markets.businessinsider.com - October 17 at 11:47 AM
Revive Therapeutics Ltd.: Revive Therapeutics Provides Update of Novel Bucillamine Formulation DevelopmentRevive Therapeutics Ltd.: Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
finanznachrichten.de - October 11 at 2:48 PM
Revive Therapeutics Provides Update of Novel Bucillamine Formulation DevelopmentRevive Therapeutics Provides Update of Novel Bucillamine Formulation Development
tmcnet.com - October 11 at 9:47 AM
Revive I-5 project continues with driving surface improvement work starting MondayRevive I-5 project continues with driving surface improvement work starting Monday
komonews.com - October 11 at 12:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

BriaCell Therapeutics logo

BriaCell Therapeutics

CVE:BCT
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Hemispherx BioPharma logo

Hemispherx BioPharma

NYSEAMERICAN:HEB
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.
Samsara logo

Samsara

NYSE:IOT
Samsara Inc. provides solutions that connects physical operations data to its connected operations cloud in the United States and internationally. The company's Connected Operations Cloud includes Data Platform, which ingests, aggregates, and enriches data from its IoT devices and has embedded capabilities for AI, workflows and analytics, alerts, API connections, and data security and privacy. Its applications include video-based safety that enables customers to build a safety program and protect their teams with AI-enabled video; vehicle telematics which provides visibility into real-time vehicle location and diagnostics with GPS tracking, routing and dispatch, fuel efficiency management, electric vehicle usage and charge planning, preventative maintenance, and insights to manage fuel and energy costs; and mobile apps and workflows that improves productivity for frontline workers and enables regulatory compliance for workers to see upcoming jobs, capture electronic documents, perform maintenance inspections, maintain compliance logs, and message with back-office administration. The company also provides equipment monitoring which offers visibility and management of unpowered and powered assets, ranging from generators and compressors to heavy construction equipment and trailers to improve operating efficiency, prevent unplanned downtime, and avoid critical safety and compliance issues; and site visibility that provides remote visibility into sites to improve onsite security, safety, and incident response times. It serves transportation, wholesale and retail trade, construction, field services, logistics, utilities and energy, healthcare and education, manufacturing, food and beverage, and other industries, as well as government. Samsara Inc. was incorporated in 2015 and is headquartered in San Francisco, California.
Nanalysis Scientific logo

Nanalysis Scientific

CVE:NSCI
Nanalysis Scientific Corp. engages in the development, manufacture, and sale of magnetic resonance products in the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: Nanalysis, RS2D, K'Prime, and Corporate. It offers nuclear magnetic resonance (NMR) spectrometers; software module packages; cutting-edge electronics components for precision analytical instruments; and services for its NMR technologies. It serves pharmaceutical, security, biotech, nutraceutical, chemical, food, materials, medical, and education industries. The company is headquartered in Calgary, Canada.
Revive Therapeutics logo

Revive Therapeutics

CVE:RVV
Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada.